LEADER 03913nam  22006015  450 
001 9910254505103321
005 20200629203346.0
010   $a3-319-23150-2
024 7 $a10.1007/978-3-319-23150-1
035   $a(CKB)3890000000002300
035   $a(EBL)4199767
035   $a(SSID)ssj0001597185
035   $a(PQKBManifestationID)16297161
035   $a(PQKBTitleCode)TC0001597185
035   $a(PQKBWorkID)14885486
035   $a(PQKB)11236403
035   $a(DE-He213)978-3-319-23150-1
035   $a(MiAaPQ)EBC4199767
035   $a(PPN)19088083X
035   $a(EXLCZ)993890000000002300
100   $a20151218d2016      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aBiologics to Treat Substance Use Disorders $eVaccines, Monoclonal Antibodies, and Enzymes /$fedited by Ivan D. Montoya
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016.
215   $a1 online resource (454 p.)
300   $aDescription based upon print version of record.
311   $a3-319-23149-9 
320   $aIncludes bibliographical references and index.
327   $aIntroduction -- PART I: Vaccines: Introduction -- Nicotine -- Cocaine -- Heroin -- Metamphetamine -- PART II: Monoclonal antibodies: Introduction -- Cocaine -- Metamphetamine -- PCP -- PART III: Enzymes: Introduction -- Butyrylcholinesterase -- Cocaine Esterase -- PART IV: New strategies to optimize the development of biologics: Adenovirus based vaccines -- Nanotechnology based vaccines -- Protein Nanoparticles -- DNA Scaffolded Vaccines -- Single Hapten Conjugate Therapeutic Vaccine -- Vaccine Adjuvants -- Laser Adjuvant -- Peptide Conjugates & Cytokine Adjuvants -- T. brucei: A Platform for Immunization -- Vaccines for SUDs and HIV infection -- New Monoclonal Antibodies -- Protein Engineered for Controlled Duration of Action -- PART V: Ethical aspects of biologics to treat SUDs.
330   $aThis book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions. Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.
606   $aPsychopharmacology
606   $aPharmacotherapy
606   $aPharmacology
606   $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
615  0$aPsychopharmacology.
615  0$aPharmacotherapy.
615  0$aPharmacology.
615 14$aPsychopharmacology.
615 24$aPharmacotherapy.
615 24$aPharmacology/Toxicology.
676   $a610
702   $aMontoya$b Ivan D$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910254505103321
996   $aBiologics to Treat Substance Use Disorders$92527138
997   $aUNINA